REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet's common stock with an exercise price of $0.65 per share, the closing price of.

Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2025. “We were pleased to announce positive preliminary data last month from seven SLE and LN patients treated in our Phase 1 trial of ADI-001, underscoring its broad potential as a t.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2025. Five individuals were hired by Adicet in October 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 97,200 shares of Adicet's common stock with an exercise price of $0.75 per share,.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston. Details of the event are as follows: Date: Tuesday, November 11, 20.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA. “Dosing the first patient in our clinical study of ADI-001 in treatment-refractory RA marks an important milestone in our Phase 1 program, which is now en.

Adicet Bio, Inc. - Special Call Company Participants Chen Schor - CEO, President & Director Julie Maltzman - Chief Medical Officer Blake Aftab - Senior VP & Chief Scientific Officer Conference Call Participants Jenna Li - Jefferies LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Karina Rabayeva - Truist Securities, Inc., Research Division John Newman - Canaccord Genuity Corp., Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Robert Burns - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, everyone, and welcome to the Adicet webcast.

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,000,000 shares of common stock. The shares of common stock are b.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in the ongoing Phase 1 study evaluating ADI-001 as a potential treatment for patients with autoimmune diseases. The data cut as of August 31, 2025, includes seven patients (five.